Study finds Sinovac vaccine 99.49 pct effective in immune responses

Photo taken on May 12, 2021 shows COVID-19 vaccine developed by Chinese pharmaceutical company Sinovac at a COVID-19 vaccination center in Bangkok, Thailand. (Xinhua/Rachen Sageamsak)

99.49 percent of the recipients of Sinovac vaccine had developed antibody responses four weeks after their second shots, the Bangkok Post said on Sunday, quoting the study results.

BANGKOK, May 19 (Xinhua) -- A new vaccination study conducted by Thailand's Chulalongkorn University has found that China's Sinovac vaccine has extremely high efficacy in boosting immune responses against COVID-19, according to media reports.

The study run by the Center of Excellence in Clinical Virology of the Faculty of Medicine at the university showed that 99.49 percent of the recipients had developed antibody responses four weeks after their second shots, the Bangkok Post said on Sunday, quoting the study results.

Three weeks after the first shot, around 66 percent of the recipients had developed immune responses, the report added.

The number of antibodies against the coronavirus was measured with Roche Elecsys Electrochemiluminescence Immunoassay, a qualitative detection of total antibodies developed against the virus in people's blood samples before and after the vaccination period, said the research group.

The tests were conducted before injections, three weeks after the first shot and four weeks after the second injection.